Bruker (BRKR) was downgraded to market perform from outperform at Leerink. $27 price target. The company may struggle to continue expanding margins in the coming quarters, Leerink said.
Bruker was also downgraded by Bank of America/Merrill Lynch, to underperform from neutral. $26 price target. The valuation isn't as attractive, as the stock is already trading north of 25 times expected 2017 earnings, analysts said.
Chemtura (CHMT) was upgraded to overweight at Keybanc. $32 price target. The stock has lagged, but favorable industry dynamics could drive earnings upside in the coming quarters, Keybanc said.
Capital One (COF) was downgraded to underperform from perform at Oppenheimer. $58 price target. Earnings estimates were also cut, given market headwinds, Oppenheimer said.
Cisco Systems (CSCO) was downgraded to neutral from buy at Bank of America/Merrill Lynch. $30 price target. The company lacks near-term catalysts, analysts said.
Fifth Third Bank (FITB) was downgraded to market perform from outperform at BMO Capital. $19 price target. The company is facing near-term earnings headwinds, BMO said.
LPL Financial (LPLA) was downgraded to sell from neutral at Goldman Sachs. The valuation isn't as attractive, as the stock is up 50% from its lows and trades at a steep premium to its peers, Goldman said.
PerkinElmer (PKI) was downgraded to neutral from buy at Bank of America/Merrill Lynch. $52 price target. The company is facing near-term margin headwinds, analysts said.
PulteGroup (PHM) was downgraded to neutral from overweight at JPMorgan. $18 price target. The CEO resignation adds uncertainty to the thesis, JPMorgan said.
Waters (WAT) was downgraded to neutral from buy at Bank of America/Merrill Lynch. $137 price target. The company trades at a premium to its peers, but faces difficult near-term comps, analysts said.
Xylem (XYL) was upgraded to buy from neutral at Sterne Agee. $52 price target. Organic revenue growth is set to accelerate, Sterne said.